Cambridge, Massachusetts, USA, November 17, 2026
Biogen has announced encouraging two-year clinical findings for diranersen, an investigational antisense oligonucleotide (ASO) therapy being developed for people with early Alzheimer’s disease. New results from the Phase 2 CELIA study, presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference, indicate that diranersen continued to slow clinical decline across measures of cognition, daily functioning and disease progression at Week 96. The 60 mg dose administered twice yearly demonstrated the largest treatment effects, with a reported 38% slowing of decline on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) scale compared with the study’s placebo-equivalent reference group. The findings provide additional evidence supporting the investigation of tau-targeting approaches in Alzheimer’s disease, although diranersen remains an investigational medicine and further clinical evaluation is required.
Two-Year CELIA Results Show Continued Clinical Benefit
According to Biogen, the two-year analysis showed that diranersen continued to demonstrate clinical effects across several measures of cognition and function. In the group receiving 60 mg every six months, the reported slowing of clinical decline on the CDR-SB measure increased from 26% at Week 76 to 38% at Week 96, corresponding to a 1.09-point treatment difference at two years. Improvements in the reported treatment effects were also observed across four other measures when the Week 96 findings were compared with the 18-month results. These included ADAS-Cog13, which measures cognitive performance, where the reported slowing increased from 42% to 54%; the Alzheimer’s Disease Composite Score (ADCOMS), which increased from 23% to 38%; the modified Integrated Alzheimer’s Disease Rating Scale (iADRS), which increased from 30% to 46%; and the Alzheimer’s Disease Cooperative Study–Activities of Daily Living scale for Mild Cognitive Impairment (ADCS-ADL-MCI), which increased from 0% to 30%. The Mini-Mental State Examination (MMSE) showed a different pattern, with the reported treatment effect changing from 50% at Week 76 to 38% at Week 96. Biogen reported that clinical benefits were observed across all studied dose groups, with the twice-yearly 60 mg regimen showing the largest effects at two years. The company also stated that diranersen was generally well tolerated through the two-year assessment, with no new safety signals identified.
Tau-Targeting Approach and CELIA Study Design
Diranersen, also known as BIIB080 or IONIS-MAPTRx, is an investigational antisense oligonucleotide designed to target messenger RNA produced by the microtubule-associated protein tau gene, known as MAPT. By targeting MAPT mRNA, the therapy is intended to reduce the production of tau protein, including both intracellular and extracellular tau. Tau accumulation and abnormal tau pathology are associated with the progression of Alzheimer’s disease and changes in cognitive function. Diranersen is designed to address tau production at the genetic-message level rather than targeting only tau proteins outside cells. The global Phase 2 CELIA trial enrolled 416 participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia. Participants had not previously received anti-amyloid therapy. The study was designed as a randomized, double-blind, placebo-controlled, dose-ranging trial and evaluated three intrathecal dosing regimens during its 18-month placebo-controlled treatment period: 60 mg every six months, 115 mg every six months and 115 mg every three months. The primary endpoint assessed dose response based on change from baseline in CDR-SB at Week 76, while secondary and exploratory assessments included additional clinical measures, cerebrospinal fluid tau biomarkers and tau positron emission tomography imaging. The two-year findings were generated during the ongoing long-term extension phase, which continues to assess the durability of clinical effects and long-term safety.
Findings Support Continued Development, With Further Testing Needed
The latest findings add to the clinical and biomarker evidence being generated for diranersen. However, the two-year treatment-effect estimates require careful interpretation because they were derived from the open-label extension phase, rather than a continued randomized, placebo-controlled comparison. The analysis compared participants who received diranersen during the controlled phase and remained on the same dose with participants originally assigned to placebo who transitioned into the extension and had received either no dose or one dose by Week 96. As participants continue through the extension, all are expected to receive diranersen. Separately, Biogen’s earlier May 2026 announcement reported that the CELIA study did not meet its primary endpoint assessing dose response at Week 76, although the company cited biomarker and prespecified clinical findings as support for further development. The new two-year results therefore represent additional evidence, but they do not establish regulatory approval or confirmatory efficacy. Biogen is continuing to evaluate diranersen’s long-term safety, tolerability and potential clinical benefit, with further development intended to determine whether the findings can be confirmed in later-stage clinical testing. The programme is part of ongoing research into therapies that target tau, one of the major biological features associated with Alzheimer’s disease. Diranersen has not been approved by any regulatory authority, and its safety and efficacy remain under clinical investigation.
Source: Biogen press release



